^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CERS4 overexpression

    i
    Other names: CERS4, Ceramide Synthase 4, LASS4, Trh1, Sphingosine N-Acyltransferase CERS4, LAG1 Longevity Assurance Homolog 4, LAG1 Homolog, Ceramide Synthase 4, FLJ12089, LAG1 Longevity Assurance Homolog 4 (S. Cerevisiae), CerS4
    Entrez ID:
    79603
    over2years
    Ceramide synthase 4 overexpression exerts oncogenic properties in breast cancer. (PubMed, Lipids Health Dis)
    Chronic CerS4 overexpression may exert oncogenic effects in breast cancer via alterations in signaling, EMT, and chemoresistance. Therefore, CerS4 may represent an attractive target for anticancer therapy, especially in LumA breast cancer.
    Journal
    |
    mTOR (Mechanistic target of rapamycin kinase) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • ABCC1 (ATP Binding Cassette Subfamily C Member 1) • ABCC2 (ATP Binding Cassette Subfamily C Member 2) • CERS4 (Ceramide Synthase 4)
    |
    CERS4 overexpression
    |
    paclitaxel • tamoxifen • doxorubicin hydrochloride
    over2years
    Ceramide synthase CERS4 gene downregulation is associated with KRAS mutation in colorectal cancer. (PubMed, Sci Rep)
    CERS4 expression was significantly reduced in KRAS mutant CRC. Moreover, CRC with decreased CERS4 showed significantly more frequent venous invasion.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CERS4 (Ceramide Synthase 4)
    |
    KRAS mutation • CERS4 overexpression